

1. Misra UK, Kalita J, Singh VK, Kumar S. A study of comorbidities in myasthenia gravis. *Acta Neurol Belg.* 2020;120(1):59-64.
2. Basoff D, Parthan A, Bandaru R, et al. Comorbidities in patients with myasthenia gravis in the USA: a retrospective claims database analysis. *Neurology.* 2023;100(17\_supplement\_2). Abstract P1-5.003.
3. Liu D, Ahmet A, Ward L, et al. A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy. *Allergy Asthma Clin Immunol.* 2013;9(1):30.
4. Johnson S, Katyal N, Narula N, Govindarajan R. Adverse side effects associated with corticosteroid therapy: a study in 39 patients with generalized myasthenia gravis. *Med Sci Monit.* 2021;27:e933296.
5. Fardet L, Petersen I, Nazareth I. Monitoring of patients on long-term glucocorticoid therapy: a population-based cohort study. *Medicine (Baltimore).* 2015;94(15):e647.
6. National Center for Immunization and Respiratory Diseases. Timing and Spacing of Immunobiologics: General Best Practice Guidelines for Immunization. Updated August 1, 2023. Accessed April 17, 2024. <https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/timing.html#print>
7. Stone JH, McDowell PJ, Jayne DRW, et al. The glucocorticoid toxicity index: measuring change in glucocorticoid toxicity over time [published correction appears in *Semin Arthritis Rheum.* 2023 Feb;58:152124]. *Semin Arthritis Rheum.* 2022;55:152010.
8. Clinical Review Report: Eculizumab (Soliris): Alexion Pharma Canada Corporation: Indication: Adult patients with generalized myasthenia gravis [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2020 Dec. Appendix 5, Description and Appraisal of Outcome Measures. <https://www.ncbi.nlm.nih.gov/books/NBK567509/>
9. Farmakidis C, Pasnoor M, Dimachkie MM, Barohn RJ. Treatment of myasthenia gravis. *Neurol Clin.* 2018;36(2):311-337.
10. Palace J, Newsom-Davis J, Lecky B. A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Myasthenia Gravis Study Group. *Neurology.* 1998;50(6):1778-1783.
11. Food and Drug Administration. Azathioprine. Prescribing information. May 2011. Accessed April 26, 2024. [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2011/016324s034s035lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/016324s034s035lbl.pdf)
12. Alhaidar MK, Abumurad S, Soliven B, Rezanian K. Current treatment of myasthenia gravis. *J Clin Med.* 2022;11(6):1597.
13. Food and Drug Administration. Eculizumab. Prescribing information. Revised June 2019. Accessed April 26, 2024. [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2019/125166s431lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/125166s431lbl.pdf)
14. Howard JF Jr, Utsugisawa K, Benatar M, et al. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. *Lancet Neurol.* 2017;16(12):976-986. Erratum in: *Lancet Neurol.* 2017;16(12):954.
15. Narayanaswami P, Sanders DB, Wolfe G, et al. International Consensus Guidance for Management of Myasthenia Gravis: 2020 update. *Neurology.* 2021;96(3):114-122.
16. Faculty communication. Ali A. Habib, MD.
17. Food and Drug Administration. Ravulizumab. Prescribing information. Revised April 2022. Accessed May 2, 2024. [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2022/761108s023lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761108s023lbl.pdf)
18. Meisel A, Annane D, Vu T, et al; CHAMPION MG Study Group. Long-term efficacy and safety of ravulizumab in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis: results from the phase 3 CHAMPION MG open-label extension. *J Neurol.* 2023;270(8):3862-3875.
19. Food and Drug Administration. Zilucoplan. Prescribing information. Revised October 2023. Accessed May 2, 2024. [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2023/216834s000lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216834s000lbl.pdf)

20. Howard JF Jr, Bresch S, Genge A, et al; RAISE Study Team. Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study. *Lancet Neurol*. 2023;22(5):395-406.
21. Sanders DB, Hart IK, Mantegazza R, et al. An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis. *Neurology*. 2008;71(6):400-406.
22. Muscle Study Group. A trial of mycophenolate mofetil with prednisone as initial immunotherapy in myasthenia gravis. *Neurology*. 2008;71(6):394-399.
23. Silvestri NJ. Myasthenia gravis: making progress for more accurate diagnoses and targeted treatments. *Pract Neurol*. 2024;23(3):29-32.
24. DeHart-McCoyle M, Patel S, Du X. New and emerging treatments for myasthenia gravis. *BMJ Med*. 2023;2(1):e000241.
25. Bril V, Drużdż A, Grosskreutz J, et al. Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study [published correction appears in *Lancet Neurol*. 2023 Oct;22(10):e11]. *Lancet Neurol*. 2023;22(5):383-394.
26. Howard JF Jr, Bril V, Vu T, et al. Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial [published correction appears in *Lancet Neurol*. 2021 Aug;20(8):e5]. *Lancet Neurol*. 2021;20(7):526-536.
27. Food and Drug Administration. FDA approves new treatment for myasthenia gravis. Posted December 17, 2021. Accessed April 17, 2024. <https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-myasthenia-gravis>
28. Food and Drug Administration. Rozanolixizumab. Prescribing information. Revised June 2023. Accessed April 17, 2024. [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2023/761286s000lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761286s000lbl.pdf)
29. Wolfe GI, Kaminski HJ, Aban IB, et al. Randomized trial of thymectomy in myasthenia gravis [published correction appears in *N Engl J Med*. 2017;376(21):2097. [Dosage error in article text]]. *N Engl J Med*. 2016;375(6):511-522.
30. Sanders DB, Wolfe GI, Benatar M, et al. International consensus guidance for management of myasthenia gravis: executive summary. *Neurology*. 2016;87(4):419-425.
31. Murai H, Utsugisawa K, Motomura M, Imai T, Uzawa A, Suzuki S. The Japanese clinical guidelines 2022 for myasthenia gravis and Lambert–Eaton myasthenic syndrome. *Clin Exp Neuroimmunol*. 2023;14(1):19-27.
32. Wiendl H, Abicht A, Chan A, et al. Guideline for the management of myasthenic syndromes. *Ther Adv Neurol Disord*. 2023;16:17562864231213240.
33. Bhandari V, Bril V. FcRN receptor antagonists in the management of myasthenia gravis. *Front Neurol*. 2023;14:1229112.